Copyright: ©Author(s) 2026.
World J Gastrointest Endosc. Oct 16, 2026; 18(10): 125564
Published online Oct 16, 2026. doi: 10.4253/wjge.125564
Published online Oct 16, 2026. doi: 10.4253/wjge.125564
Table 3 Logistic regression of factors associated with endoscopic remission (n = 23)
| Characteristics | Univariate | Multivariate | ||||
| OR | 95%CI | P value | OR | 95%CI | P value | |
| Female | 2.75 | 0.76-9.95 | 0.123 | 5.92 | 1.10-32.0 | 0.039 |
| Crohn’s disease | 0.37 | 0.10-1.36 | 0.135 | 0.17 | 0.03-0.93 | 0.041 |
- Citation: Kitsou V, Kokkotis G, Avatziadis P, Ioannou A, Michopoulos S, Zampeli E, Bamias G. Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease. World J Gastrointest Endosc 2026; 18(10): 125564
- URL: https://www.wjgnet.com/1948-5190/full/v18/i10/125564.htm
- DOI: https://dx.doi.org/10.4253/wjge.125564